The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor

Recruiting now

Conditions studied: Fibromyalgia

In brief

Fibromyalgia is a chronic pain syndrome characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, and cognitive symptoms. Central sensitization is considered a key mechanism in the pathophysiology of fibromyalgia; however, the underlying biological markers have not been fully clarified. Brain-derived neurotrophic factor (BDNF) and S100B protein have been suggested to play roles in neuroinflammation and central pain processing. This observational, cross-sectional study aims to evaluate serum S100B and BDNF levels in patients with fibromyalgia and to investigate their relationship with central sensitization and sleep quality. Serum biomarker levels and clinical assessment scales will be compared between patients with fibromyalgia and healthy controls.

Key facts

Study ID

NCT07358754

Run by

Kanuni Sultan Suleyman Training and Research Hospital

People needed

60

Starts

2026-02-01

Expected to finish

2026-04-30

Last updated by the study team

2026-04-15

Who can join

Age: 18 and older, up to 50. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Female participants aged between 18 and 50 years
• Diagnosis of fibromyalgia according to 2016 American College of Rheumatology (ACR) criteria
• Symptoms present for at least 3 months
• Ability to understand and complete study questionnaires
• Provision of written informed consent
• For healthy controls:
• No diagnosis of fibromyalgia or chronic widespread pain
• No known systemic disease

Where it is running

• Kanuni Sultan Süleyman Training and Research Hospital — Istanbul, Turkey (Türkiye) (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.